CCLD stock forecast, quote, news & analysis
CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U... Show more
Why CareCloud (CCLD) Is Up +47% in the Last 30 Days
Key Takeaways
- CCLD stock surged +47% over the past 30 days, driven primarily by strong full-year 2025 earnings reported on March 12, featuring record net income and the first positive full-year EPS since IPO.
- Over the past quarter, shares gained +24%, supported by AI product launches, capital structure simplification, and revenue growth exceeding guidance.
- Key catalysts include robust Q4 revenue beat, entry into inpatient software via Medsphere acquisition, and positive cash flow generation amid healthcare IT demand.
- Recent volatility tied to cybersecurity disclosure and analyst commentary, but overall sentiment bolstered by profitability streak and growth outlook reaffirmation.
- Trading above 50-day moving average signals bullish short-term trend in healthcare technology sector.
CareCloud (CCLD) Company Overview and Market Position
CareCloud, Inc. (CCLD) is a healthcare technology company providing cloud-based software-as-a-service (SaaS) solutions, revenue cycle management (RCM), and electronic health records (EHR) for medical practices. Its core business model revolves around subscription-based platforms that streamline practice management, patient engagement, and billing, supplemented by AI-driven tools for efficiency.
Operating in the competitive healthcare IT industry, CareCloud differentiates through cost-effective offshore operations and generative AI innovations. With a focus on small to mid-sized practices, its fundamentals—recurring revenue, seven straight quarters of GAAP profitability, and expanding margins—explain recent price strength, as investors reward the shift from losses to consistent earnings in a sector favoring scalable tech amid rising healthcare digitization.
CareCloud (CCLD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CCLD stock rose from approximately $2.46 to $3.62, marking a +47% gain. The movement was volatile yet trend-driven, with a sharp rally post-earnings on March 12 (from $2.91 to highs near $3.81 by late March), followed by consolidation around $3.50-$3.65 amid high volume days exceeding 900,000 shares.
For the past quarter, shares advanced +24% from around $2.91 in early January to the current $3.62. Performance featured steady uptrend interrupted by dips, trading above the 50-day moving average of $2.85 while beta of 2.15 reflects sector volatility. Market cap stands at $154 million, within a 52-week range of $1.14-$4.01.
What Drove CCLD Stock Price in the Last 30 Days
The primary catalyst was CareCloud's March 12 earnings release, reporting full-year 2025 revenue of $120.5 million (up 9% YoY), GAAP net income of $10.8 million (first positive full-year EPS of $0.10 since 2014 IPO), and Q4 revenue of $34.4 million beating estimates. Adjusted EBITDA hit 23% margins, with $28.6 million operating cash flow highlighting financial health.
Company-specific news amplified gains: Preferred A stock conversions simplified capital structure, AI product introductions like next-gen MAP App at HFMA conference, and Medsphere acquisition entry into inpatient EHR. Analyst notes on AI push and profitability sustained momentum, despite minor pullback from Roth Capital's aircraft purchase critique and cybersecurity incident disclosure affecting health records. These factors connected directly to price surge, with post-earnings volume spiking and shares hitting 52-week highs near $3.81.
What Drove CCLD Stock Performance Over the Last Quarter
The quarter's +24% rise stemmed from sustained narratives of transformation: Q4 results capped seven consecutive profitable quarters, revenue growth from acquisitions like Medsphere, and AI integrations boosting RCM efficiency. Healthcare IT demand, fueled by regulatory pushes for digitization and cost controls, favored CareCloud's model.
Macro tailwinds included stable interest rates supporting growth stocks, while institutional interest grew amid cash flow strength ($28.6 million YoY). Competitive positioning strengthened via offshore cost advantages (Pakistan/Sri Lanka operations) and Nasdaq compliance regain. Cumulative impact: outperformance versus peers, with YTD gains of 24% versus broader market.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, which analyze and trade thousands of tickers across various strategies like trend-following, mean reversion, and momentum plays. These bots differ in timeframe (intraday to long-term), risk profiles, and metrics such as win rate, Sharpe ratio, and maximum drawdown. Curated based on recent performance and relevance, the section highlights bots excelling in current market trends, offering transparency via backtested and live results. Explore these tools to enhance your stock analysis and potentially automate trading decisions with data-driven insights.
CCLD Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming quarterly earnings for sustained profitability and revenue trajectory toward 2026 guidance. Track AI adoption rates, Medsphere integration progress, and RCM platform enhancements amid healthcare digitization trends.
Macro factors like interest rates, inflation impacting healthcare spending, and regulatory changes (e.g., interoperability rules) remain key. Strategic developments including further M&A (mergers and acquisitions), capital structure resolutions, and Nasdaq compliance. Risks encompass cybersecurity threats, execution on AI rollout, and sector competition; catalysts could include analyst upgrades or partnership announcements.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
CCLD's Stochastic Oscillator is remaining in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CCLD's RSI Oscillator exited the oversold zone, of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CCLD advanced for three days, in of 239 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CCLD as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CCLD turned negative on June 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 50-day moving average for CCLD moved below the 200-day moving average on May 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCLD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CCLD broke above its upper Bollinger Band on June 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CCLD entered a downward trend on May 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.545) is normal, around the industry mean (7.367). P/E Ratio (16.308) is within average values for comparable stocks, (49.962). CCLD's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.152). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (0.728) is also within normal values, averaging (5.631).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CCLD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical billing and transcription services
Industry ServicestotheHealthIndustry